Safety, pharmacokinetics, pharmacodynamics, and plasma lipoprotein distribution of eritoran (E5564) during continuous intravenous infusion into healthy volunteers

Antimicrobial Agents and Chemotherapy

Volumn 48, Issue 9, 2004, Pages 3233-3240

  Rossignol, Daniel P ^a   Wasan, Kishor M ^b   Choo, Eugene ^b   Yau, Edwin ^b   Wong, Nancy ^c   Rose, Jeffrey ^c   Moran, Jeffrey ^d   Lynn, Melvyn ^a  

^a EISAI INC   (United States)

^b UNIVERSITY OF BRITISH COLUMBIA   (Canada)

^c EISAI RESEARCH INSTITUTE   (United States)

^d Harris Laboratories Inc Lincolnshire   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALBUMIN; E 5564; ERITORAN; HIGH DENSITY LIPOPROTEIN; LIPID A DERIVATIVE; LIPOPOLYSACCHARIDE; LOW DENSITY LIPOPROTEIN; UNCLASSIFIED DRUG; VERY LOW DENSITY LIPOPROTEIN;

AREA UNDER THE CURVE; ARTICLE; CLINICAL TRIAL; CONCENTRATION RESPONSE; CONTINUOUS INFUSION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISTRIBUTION VOLUME; DOUBLE BLIND PROCEDURE; DRUG BLOOD LEVEL; DRUG DISTRIBUTION; DRUG HALF LIFE; DRUG PROTEIN BINDING; DRUG SAFETY; DRUG TOLERABILITY; ENDOTOXEMIA; HEADACHE; HUMAN; HUMAN EXPERIMENT; LIPOPROTEIN BLOOD LEVEL; LOW DRUG DOSE; MALE; NORMAL HUMAN; PHLEBITIS; PLASMA CLEARANCE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RHINITIS; SIDE EFFECT;

AREA UNDER CURVE; BIOLOGICAL ASSAY; BLOOD PROTEINS; DOSE-RESPONSE RELATIONSHIP, DRUG; DOUBLE-BLIND METHOD; HALF-LIFE; HUMANS; INDICATORS AND REAGENTS; INFUSIONS, INTRAVENOUS; LIPID A; LIPOPOLYSACCHARIDES; LIPOPROTEINS; LIPOPROTEINS, HDL; LIPOPROTEINS, LDL; PROTEIN BINDING; SERUM ALBUMIN; TRIGLYCERIDES; TUMOR NECROSIS FACTOR-ALPHA;

EID: 3142742677     PISSN: 00664804     EISSN: None     Source Type: Journal    
DOI: 10.1128/AAC.48.9.3233-3240.2004     Document Type: Article

References (18)

1. Du, X., A. Poltorak, M. Silva, and B. Beutler. 1999. Analysis of Tlr4-mediated LPS signal transduction in macrophages by mutational modification of the receptor. Blood Cells Mol. Dis. 25:328-338.
2. Kaneko, K., R. Ueda, K. Kikuchi, Y. Sano, and T. Yoshimura. 1999. Quantitative determination of a potent lipopolysaccharide antagonist, E5564, in rat and dog plasma by high-performance liquid chromatography with fluorescence detection. J. Chromatogr. B Biomed. Sci. Appl. 736:67-75.
3. Lynn, M., D. P. Rossignol, J. L. Wheeler, R. J. Kao, C. A. Perdomo, R. Noveck, R. Vargas, T. D'Angelo, S. Gotzkowsky, and F. G. McMahon. 2003. Blocking of responses to endotoxin by E5564 in healthy volunteers with experimental endotoxemia. J. Infect. Dis. 187:631-639.
4. Mullarkey, M., J. R. Rose, J. Bristol, T. Kawata, A. Kimura, S. Kobayashi, M. Przetak, J. Chow, F. Gusovsky, W. J. Christ, and D. P. Rossignol. 2003. Inhibition of endotoxin response by E5564, a novel Toll-like receptor 4-directed endotoxin antagonist. J. Pharmacol. Exp. Ther. 304:1093-1102.
5. Poltorak, A., X. He, I. Smirnova, M. Y. Liu, C. V. Huffel, X. Du, D. Birdwell, E. Alejos, M. Silva, C. Galanos, M. Freudenberg, P. Ricciardi-Castagnoli, B. Layton, and B. Beutler. 1998. Defective LPS signaling in C3H/HeJ and C57BL/10ScCr mice: mutations in Tlr4 gene. Science 282:2085-2088.
6. Ramaswamy, M., T. L. Wallace, P. A. Cossum, and K. M. Wasan. 1999. Species differences in the proportion of plasma lipoprotein lipid carried by high-density lipoproteins influence the distribution of free and liposomal nystatin in human, dog, and rat plasma. Antimicrob. Agents Chemother. 43:1424-1428.
7. Rose, J. R., W. J. Christ, J. R. Bristol, T. Kawata, and D. P. Rossignol. 1995. Agonistic and antagonistic activities of bacterially derived Rhodobacter sphaeroides lipid A: comparison with activities of synthetic material of the proposed structure and analogs. Infect. Immun. 63:833-839.
8. Rose, J. R., M. A. Mullarkey, W. J. Christ, L. D. Hawkins, M. Lynn, Y. Kishi, K. M. Wasan, K. Peteherych, and D. P. Rossignol. 2000. Consequences of interaction of a lipophilic endotoxin antagonist with plasma lipoproteins. Antimicrob. Agents Chemother. 44:504-510.
9. Rossignol, D. P., W. J. Christ, L. D. Hawkins, S. Kobayashi, T. Kawata, M. Lynn, I. Yamatsu, and Y. Kishi. 1999. Synthetic endotoxin antagonists, p. 699-717. In H. Brade, S. M. Opal, S. N. Vogel, and D. C. Morrison (ed.), Endotoxin in health and disease. Marcel Dekker, Inc., New York, N. Y.
10. Rossignol, D. P., and M. Lynn. 2003. Antagonism of in vivo and ex vivo response to endotoxin by E5564, a novel synthetic lipid A antagonist. J. Endotoxin Res. 8:483-488.
11. Suganuma, A., D. P. Rossignol, K. Kaneko, A. W. LaRochelle, and W. D. Kerns. 2000. Clinical pharmacology of E5564, a lipid A antagonist, in a canine lipopolysaccharide challenge model. J. Endotoxin Res. 6:115.
12. Wasan, K. M., and S. M. Cassidy. 1998. Role of plasma lipoproteins in modifying the biological activity of hydrophobic drugs. J. Pharm. Sci. 87:411-424.
13. Wasan, K. M., S. M. Cassidy, M. Ramaswamy, A. Kennedy, F. W. Strobel, S. P. Ng, and T. Y. Lee. 1999. A comparison of step-gradient and sequential density ultracentrifugation and the use of lipoprotein deficient plasma controls in determining the plasma lipoprotein distribution of lipid-associated nystatin and cyclosporine. Pharm. Res. 16:165-169.
14. Wasan, K. M., P. H. Pritchard, M. Ramaswamy, W. Wong, E. M. Donnachie, and L. J. Brunner. 1997. Differences in lipoprotein lipid concentration and composition modify the plasma distribution of cyclosporine. Pharm. Res. 14:1613-1620.
15. Wasan, K. M., O. Sivak, R. Cote, A. M. MacInnes, K. D. Boulanger, M. Lynn, W. J. Christ, L. D. Hawkins, and D. P. Rossignol. 2003. Association of the endotoxin antagonist E5564 with high-density lipoproteins in vitro: dependence on low-density and triglyceride-rich lipoprotein concentration. Antimicrob. Agents Chemother. 47:2796-2803.
16. Wasan, K. M., F. W. Strobel, S. C. Parrott, M. Lynn, W. J. Christ, L. D. Hawkins, and D. P. Rossignol. 1999. Lipoprotein distribution of a novel endotoxin antagonist, E5531, in plasma from human subjects with various lipid levels. Antimicrob. Agents Chemother. 43:2562-2564.
17. Wong, Y. N., D. Rossignol, J. R. Rose, R. Kao, A. Carter, and M. Lynn. 2003. Safety, pharmacokinetics and pharmacodynamics of E5564, a lipid A antagonist, during an ascending single-dose clinical study. J. Clin. Pharmacol. 43:735-742.
18. Zar, J. H. 1984. Multiple regression and correlation in biostatistical analysis. Prentice-Hall, Inc., Englewood, N.J.